November 16, 2022 Acad, Gov/Utilities PR/Corporate Roche receives U.S. FDA Emergency Use Authorization for its high-throughput test to detect monkeypox virus Read more
November 14, 2022 Bio/Pharma/CRO [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease Read more
November 3, 2022 Acad, Gov/Utilities Product Launch Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs Read more
October 27, 2022 Bio/Pharma/CRO Positive topline phase III results show Roche's Vabysmo improved vision for people living with retinal vein occlusion (RVO) Read more
October 26, 2022 Uncategorized Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile Read more
October 24, 2022 Acad, Gov/Utilities Life Science Tools Microscopy PR/Corporate Roche receives FDA clearance for COVID-19 PCR test for use on cobas 6800/8800 Systems Read more
October 19, 2022 Atomic Spectroscopy Licensing, IP, and Legal Product Launch Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022 Read more
October 18, 2022 Uncategorized [Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022 Read more
October 12, 2022 Uncategorized Roche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”) under CE Mark for self-test and professional use Read more
October 12, 2022 Product Launch Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA) Read more
